SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Sun Yat-sen — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSun Yat-sen
Date of birth1866-11-12
IdentifiersMRN HR-ET016-SYN-TD; SSN (made up) 000-16-4183
Document date1924-10-26
AuthorWen-Li Huang, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Before cycle 8: restaging CT, side effects, low magnesium, and the plan for maintenance. [S]

History of Present Illness

Mr. Sun returns before his eighth and last cycle of chemotherapy, five weeks after his preventive visit. Cycles 4 to 7 were given on schedule; the cold he had during cycle 5 settled without fever. For two weeks he has had a light tingling in his fingertips that does not affect buttoning or writing. He has had muscle cramps in his calves at night. He has no diarrhea, rash, cough or breathlessness, and no hearing change. His weight is steady. The ache under his ribs has gone most days. His HIV test from the preventive visit was negative. The restaging CT and HBV DNA four days ago are back. [S]

ElementDetail
CyclesSeven, on schedule
New symptomsFingertip tingling for two weeks; night cramps in the calves
Immune-related symptomsNone
WeightSteady
ResultsHIV test negative; restaging CT and HBV DNA back

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired after infusions; weight 59.6 kg; no fever
MusculoskeletalPositiveNight cramps in both calves
NeurologicalPositiveLight tingling in the fingertips; no weakness; buttons and writes normally
Ears, nose, mouth, and throatNegativeNo tinnitus or hearing change
GastrointestinalNegativeAche mostly gone; nausea mild after infusions; no diarrhea
RespiratoryNegativeNo cough or breathlessness

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a dayTwo tablets by mouth every 8 hours as needed, no more than 3,000 mg a dayOral route1924-05-04activeS
Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycleDays 1 and 8 of each 21-day cycle, up to 8 cyclesIntravenous route1924-06-01activeS
Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycleDays 1 and 8 of each 21-day cycle, up to 8 cycles, with hydrationIntravenous route1924-06-01activeS
Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycleDay 1 of each 21-day cycle with chemotherapy, then every 4 weeks aloneIntravenous route1924-06-01activeS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet by mouth every 8 hours as needed for nauseaOral route1924-06-01activeS
Magnesium oxide 400 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1924-10-26activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1924-10-26Body height165cmS
1924-10-26Body weight59.6kgS
1924-10-26Body mass index (BMI) [Ratio]21.9kg/m2S
1924-10-26Systolic blood pressure124mm[Hg]S
1924-10-26Diastolic blood pressure78mm[Hg]S
1924-10-26Heart rate80/minS
1924-10-26Respiratory rate16/minS
1924-10-26Body temperature36.6CelS
1924-10-26Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1924-10-26Leukocytes [#/volume] in Blood by Automated count4.310*3/uL4-11 10*3/uLNormalS
1924-10-26Neutrophils [#/volume] in Blood by Automated count2.110*3/uL1.8-7.7 10*3/uLNormalS
1924-10-26Hemoglobin [Mass/volume] in Blood10.7g/dL13.2-17.1 g/dLLowS
1924-10-26Platelets [#/volume] in Blood by Automated count17610*3/uL150-400 10*3/uLNormalS
1924-10-26Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1924-10-26Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
1924-10-26Creatinine [Mass/volume] in Serum or Plasma0.95mg/dL0.74-1.35 mg/dLNormalS
1924-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1919)/1.73 sq M93mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1924-10-26Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
1924-10-26Magnesium [Mass/volume] in Serum or Plasma1.6mg/dL1.7-2.2 mg/dLLowS
1924-10-26Albumin [Mass/volume] in Serum or Plasma3.7g/dL3.5-5 g/dLNormalS
1924-10-26Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.2-1.2 mg/dLNormalS
1924-10-26Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma141U/L40-129 U/LHighS
1924-10-26Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L10-40 U/LNormalS
1924-10-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-55 U/LNormalS
1924-10-26Thyrotropin [Units/volume] in Serum or Plasma3.1m[IU]/L0.45-4.5 mIU/LNormalS
1924-10-26Cancer Ag 19-9 [Units/volume] in Serum or Plasma121U/mL<=35 U/mLHighS
1924-10-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1924-10-26ECOG Performance Status score1{score}S

Physical Exam

Vital signs recorded on 1924-10-26; see the Vital Signs section. [S]

SystemFinding
GeneralThin, well; blood pressure 124/78, pulse 80; weight 59.6 kg; no jaundice
AbdomenLiver edge 2 cm below the right costal margin; no ascites
NeurologicalVibration slightly reduced at the fingertips; light touch, strength and reflexes normal
SkinNo rash; port site clean

Problems

ProblemClinical statusVerificationCodeProvenance
Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arrangedresolvedconfirmed R19.01S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis.
Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinomaactiveconfirmed C23S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy.
Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitoredactiveconfirmed Z86.19S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis.
Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectableactiveconfirmed C78.6S — Synthetic finding anchored to the peritoneal metastases reported at autopsy.
Acute viral upper respiratory infection on day 10 of cycle 5 of chemoimmunotherapy: sore throat, runny nose and dry cough for three days, afebrile, with a neutrophil count of 1.6 x10^3/uL; rapid tests for SARS-CoV-2 and influenza negative; no sign of pneumonia or pneumonitis; resolvedresolvedconfirmed J06.9S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingCT of the chest, abdomen and pelvisAt staging, then every 2 to 3 months on treatmentCompleted todayFour days ago: mass 4.9 cm; partial response, sum down 33% from baseline; no new lesions
LaboratoryCA 19-9 (and CEA when raised)At diagnosis, then with each cycle or restagingCompleted todayCA 19-9 121 U/mL
LaboratoryBlood count with neutrophilsBefore every dose (days 1 and 8)Completed todayWhite cells 4.3, neutrophils 2.1, hemoglobin 10.7 g/dL, platelets 176
LaboratoryCreatinine and eGFRBefore every dose (days 1 and 8)Completed todayCreatinine 0.95 mg/dL, eGFR 93
LaboratoryMagnesium and potassiumBefore every dose (days 1 and 8)Completed todayMagnesium 1.6 mg/dL (low), potassium 4.1 mmol/L, sodium 137 mmol/L; magnesium oxide started
LaboratoryLiver tests (bilirubin, alkaline phosphatase, AST, ALT, albumin)Before every dose (days 1 and 8)Completed todayBilirubin 0.6 mg/dL, alkaline phosphatase 141, AST 31, ALT 28 U/L, albumin 3.7 g/dL
LaboratoryTSHBaseline, then every 4 to 6 weeks on durvalumabCompleted today3.1 mIU/L
LaboratoryGlucoseBaseline, then with each pre-dose chemistry panel on durvalumabCompleted today96 mg/dL
LaboratoryHBV DNA and ALT (resolved hepatitis B)Every 3 months during treatment and for 6 to 12 months afterCompleted todayHBV DNA undetectable four days ago; ALT 28 U/L
Medication safetyImmune-related side effects (diarrhea, rash, cough or breathlessness, fatigue, endocrine symptoms)Every visitCompleted todayNone
Medication safetyChemotherapy side effects: nausea, fatigue, neuropathy, hearingEvery visitCompleted todayGrade 1 sensory neuropathy; night cramps with low magnesium
ExaminationHearing (cisplatin)Baseline before cisplatin, then by symptoms each cycleCompleted todayNo hearing symptoms; the audiogram is not needed unless symptoms appear
SurveyECOG performance statusEvery visitCompleted todayECOG 1
ExaminationWeight and nutritionEvery visitCompleted today59.6 kg, within 0.4 kg of the start of treatment
SurveyPainEvery visitCompleted today0 to 1 of 10
SurveyDistress and depression (PHQ-9)At each change in treatment or statusCompleted todayPHQ-9 4
ReferralSpecialist palliative careFrom the diagnosis of advanced cancerCompleted todaySeen every 3 to 4 weeks
Self-managementGoals of care and advance care planningAt diagnosis and at each change in treatmentCompleted todayGoals reviewed with the move to maintenance; agent named at the preventive visit
Self-managementVaccination reviewYearly and during treatmentCompleted todayInfluenza, COVID-19 and PCV20 at the preventive visit; first recombinant zoster dose today

Goal progress:

Immunizations given today: Recombinant zoster vaccine, first of two doses [S]

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022); Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021); Adult Immunization Schedule by Medical Condition and Other Indication (2026)

Follow-up: Cycle 8 day 8 next week. Durvalumab maintenance every 4 weeks from four weeks after today. Second zoster dose in one to two months. Restaging CT in 2 to 3 months. [S]